Rising incidence, no change in survival and decreasing mortality from thyroid cancer in The Netherlands since 1989

Endocrine-Related Cancer

Volumn 20, Issue 2, 2013, Pages 263-271

  Husson, Olga ^a,b   Haak, Harm R ^c   Van Steenbergen, Liza N ^b   Nieuwlaat, Willy Anne ^d   Van Dijk, Boukje A C ^e   Nieuwenhuijzen, Grard A P ^f   Karim Kos, Henrike ^g   Kuijpens, Johannes L ^h   Van De Poll Franse, Lonneke V ^a,b   Coebergh, Jan Willem W ^b,g  

^a TILBURG UNIVERSITY   (Netherlands)

^b The Netherlands   (Netherlands)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

^d CPRLab   (Netherlands)

^e Netherlands Comprehensive Cancer Organization   (Netherlands)

^f CATHARINA HOSPITAL   (Netherlands)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h VGZ Health Insurance Company   (Netherlands)

Author keywords

Histology; Incidence; Mortality; Survival; Thyroid carcinoma; Time trends

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

AGED; CARCINOMA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; THYROID NEOPLASMS;

EID: 84876780907     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0336     Document Type: Article

References (33)

1. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, Livolsi VA, Mandel SJ et al. 2012 Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. New England Journal of Medicine 367 705-715. (doi:10.1056/NEJMoa1203208)
2. Cardis E, KrewskiD, Boniol M, Drozdovitch V, Darby SC, Gilbert ES, Akiba S, Benichou J, Ferlay J, Gandini S et al. 2006 Estimates of the cancer burden in Europe from radioactive fallout from the Chernobyl accident. International Journal of Cancer 119 1224-1235. (doi:10.1002/ijc.22037)
3. Ceresini G, Corcione L, Michiara M, Sgargi P, Teresi G, Gilli A, Usberti E, Silini E & Ceda GP 2012 Thyroid cancer incidence by histological type and related variants in a mildly iodine-deficient area of Northern Italy, 1998 to 2009. Cancer 118 5473-5480.
4. Dal Maso L, Lise M, Zambon P, Falcini F, Crocetti E, Serraino D, Cirilli C, Zanetti R, Vercelli M, Ferretti S et al. 2011 Incidence of thyroid cancer in Italy, 1991-2005: time trends and age-period-cohort effects. Annals of Oncology 22 957-963. (doi:10.1093/annonc/mdq467)
5. Davies L & Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 295 2164-2167. (doi:10.1001/jama.295.18.2164)
6. Ederer F & Heise H 1959 Instructions to IBM 650 programmers in processing survival computations. Bethesda, MD, USA: National Cancer Institute. Ferlay J, Shin HR, Bray F, Forman D, Mathers C & Parkin DM2010 Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 127 2893-2917. (doi:10.1002/ijc.25516)
7. Fritz A, Percy C, Jack A, et al. 2000 In International Classification of Diseases for Oncology. Geneva, Switzerland: World Health Organisation. Harach HR, Franssila KO & Wasenius VM 1985 Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 56 531-538. (doi:10.1002/1097-0142(19850801)56:3! 531::AID- CNCR2820560321O3.0.CO;2-3)
8. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD & Griggs JJ 2011 Use of radioactive iodine for thyroid cancer. Journal of the American Medical Association 306 721-728. (doi:10.1001/jama.2011.1139)
9. Hermanek P & Sobin LH 1987 In TNM Classification of Malignant Tumours. Berlin, Germany: Springer-Verlag.
10. Husson O,Haak HR, Oranje WA, Mols F, Reemst PH& van de Poll-Franse LV 2011 Health-related quality of life among thyroid cancer survivors: a systematic review. Clinical Endocrinology 75 544-554. (doi:10.1111/j.1365-2265. 2011.04114.x)
11. Husson O, Haak HR, Buffart LM, Nieuwlaat W, Oranje WA, Mols F, Kuijpens JL, Coebergh JW& Van de Poll-Franse LV 2013 Health-related quality of life and disease specific symptoms among (long-term) thyroid cancer survivors: a study from the population-based PROFILES registry. Acta Oncologica 52 249-258. (doi:10.3109/0284186X.2012.741326)
12. Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL & Groome PA 2007 Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ: Canadian Medical Association Journal 177 1357-1361. (doi:10.1503/cmaj.061730)
13. Kim HJ, Fay MP, Feuer EJ & Midthune DN 2000 Permutation tests for joinpoint regression with applications to cancer rates. Statistics in Medicine 19 335-351. (doi:10.1002/(SICI)1097-0258(20000215):3!335::AID-SIM336O3.0.CO;2-Z)
14. Kitahara CM, Platz EA, Freeman LE, Hsing AW, LinetMS, Park Y, Schairer C, Schatzkin A, Shikany JM & Berrington de Gonzalez A 2011 Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiology, Biomarkers & Prevention 20 464-472. (doi:10.1158/1055-9965.EPI-10-1220)
15. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M et al. 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19 565-612. (doi:10.1089/thy.2008.0403)
16. Kuijpens JL, Hansen B, Hamming JF, Ribot JG, Haak HR & Coebergh JW 1998 Trends in treatment and long-term survival of thyroid cancer in Southeastern Netherlands, 1960-1992. European Journal of Cancer 34 1235-1241. (doi:10.1016/S0959-8049(98)00133-6)
17. Liu XH, Chen GG, Vlantis AC & van Hasselt CA 2009 Iodine mediated mechanisms and thyroid carcinoma. Critical Reviews in Clinical Laboratory Sciences 46 302-318. (doi:10.3109/10408360903306384)
18. Momesso DP, Vaisman F, Cordeiro de Noronha Pessoa CH, Corbo R & VaismanM2012 Small differentiated thyroid cancer: time to reconsider clinical management and treatment. Surgical Oncology [in press].
19. Netea-Maier RT, Aben KK, CasparieMK, den Heijer M, Grefte JM, Slootweg P & Hermus A 2008 Trends in incidence and mortality of thyroid carcinoma in The Netherlands between 1989 and 2003: correlation with thyroid fine-needle aspiration cytology and thyroid surgery. International Journal of Cancer 123 1681-1684. (doi:10.1002/ijc.23678)
20. Orita Y, Sugitani I, Amemiya T & Fujimoto Y 2011 Prospective application of our novel prognostic index in the treatment of anaplastic thyroid carcinoma. Surgery 150 1212-1219. (doi:10.1016/j.surg.2011.09.005)
21. Pacini F 2012 Thyroid microcarcinoma. Best Practice & Research. Clinical Endocrinology & Metabolism 26 381-389. (doi:10.1016/j.beem. 2011.10.006)
22. Pacini F, Castagna MG, Brilli L & Pentheroudakis G 2010 Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Annals of Oncology 21 (Suppl 5) v214-v219. (doi:10.1093/annonc/mdq190)
23. Schneider AB & Sarne DH 2005 Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. Nature Clinical Practice. Endocrinology & Metabolism 1 82-91. (doi:10.1038/ncpendmet0022)
24. Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffe S, Pochart JM, Cochet I, Crevisy E, Dalac A et al. 2012 Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism 97 1526-1535. (doi:10.1210/jc.2011-2512)
25. Sipos JA &Mazzaferri EL 2010 Thyroid cancer epidemiology and prognostic variables. Clinical Oncology 22 395-404. (doi:10.1016/j.clon.2010. 004)
26. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS et al. 2012 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22 1104-1139. (doi:10.1089/thy.2012.0302)
27. Sobin LH & Fleming ID 1997 TNM Classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80 1803-1804. (doi:10.1002/(SICI)1097- 0142(19971101)80:9!1803::AID-CNCR16O 3.0.CO;2-9)
28. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L & Kunkler I 2007 Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncology 8 784-796. (doi:10.1016/S1470-2045(07)70246-2)
29. Wang CC, Friedman L, Kennedy GC, Wang H, Kebebew E, Steward DL, Zeiger MA, Westra WH, Wang Y, Khanafshar E et al. 2011 A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid 21 243-251. (doi:10.1089/thy.2010.0243)
30. Welch HG & BlackWC2010 Overdiagnosis in cancer. Journal of the National Cancer Institute 102 605-613. (doi:10.1093/jnci/djq099)
31. Wittekind C, Compton CC, Greene FL & Sobin LH 2002 TNM residual tumor classification revisited. Cancer 94 2511-2516. (doi:10.1002/cncr.10492)
32. Yu GP, Li JC, Branovan D, McCormick S & Schantz SP 2010 Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid 20 465-473. (doi:10.1089/thy.2008.0281)
33. van der Zwan JM, Mallone S, van Dijk B, Bielska-Lasota M, Otter R, Foschi R, Baudin E & Links TP 2012 Carcinoma of endocrine organs: results of the RARECARE project. European Journal of Cancer 48 1923-1931. (doi:10.1016/j.ejca. 2012.01.029)